Blueprint Medicines Corporation
Blueprint Medicines Corporation (BPMC) Stock Overview
Explore Blueprint Medicines Corporation’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
8.4B
P/E Ratio
-52.87
EPS (TTM)
$-2.51
ROE
-0.49%
BPMC Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Blueprint Medicines Corporation (BPMC) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 77.85, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $146.62.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -52.87 and a market capitalization of 8.4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.